Introduction: This review provides an overview of data from trials and real-world studies available for SB5 (ImraldiTM) across three main therapeutic areas: rheumatology, gastroenterology, and dermatology.
Areas covered: A literature search for publications on data for SB5 efficacy/effectiveness, safety, and immunogenicity was undertaken.
Expert opinion: Evidence derived from clinical studies suggest that the biosimilar SB5 is a safe and effective alternative to reference adalimumab. Considering that patients suffering from immune-mediated inflammatory diseases such as inflammatory arthritis, inflammatory bowel disease and psoriasis often require long-term biologic treatment, biosimilar medicines (such as SB5) can reduce healthcare costs while increasing access to effective treatments.
Keywords: Biosimilar; Imraldi®; SB5; adalimumab; anti-TNF; dermatology; gastroenterology; multidisciplinary; rheumatology.